The polite version of longevity is sleep, supplements and zone-two cardio. The frontier that actually moved capital this past year was stranger, and far more investable: cellular reprogramming reached its first patient, pharmaceutical capital moved into aging biology, and the field's harder questions, from embryo editing to the unregulated edge, came into the open. A clear-eyed look at how to tell a genuine breakthrough from an expensive one.